Targeting the dNTP supply through anti-folates, thymidylate synthetase (TYMS) or ribonucleotide reductase (RNR) inhibitors has remained the backbone for anticancer treatments for over half a century, and provoking replication stress through inhibition of PARP or other DNA repair proteins remains a key area for future cancer therapies [5]. The gene discussed is NR2E3; the disease is cancer.